Rubraca as Maintenance Therapy Seen to Aid Survival Without Disease Progression in Range of Patients

Rubraca as Maintenance Therapy Seen to Aid Survival Without Disease Progression in Range of Patients
Rubraca (rucaparib) maintenance treatment significantly improved survival without further disease progression among ovarian cancer patients taking part in a Phase 3 clinical trial, researchers showed in a presentation at the ongoing European Society for Medical Oncology (ESMO) 2017 Congress in Madrid. The treatment benefitted patients with different types of genetic flaws that impact their ability to repair damaged

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *